Scarica l'app Stockscreener
17.24
0.23%
-0.04
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$17.28
Aprire:
$17.28
Volume 24 ore:
7.36M
Relative Volume:
0.68
Capitalizzazione di mercato:
$20.08B
Reddito:
$14.57B
Utile/perdita netta:
$-296.50M
Rapporto P/E:
-66.56
EPS:
-0.259
Flusso di cassa netto:
$1.64B
1 W Prestazione:
-0.29%
1M Prestazione:
+8.22%
6M Prestazione:
+30.51%
1 anno Prestazione:
+84.39%
Intervallo 1D:
$17.20
$17.49
Intervallo di 1 settimana:
$16.75
$17.68
Portata 52W:
$8.625
$17.68
Viatris Inc Stock (VTRS) Company Profile
Nome
Viatris Inc
Settore
Telefono
(724) 514-1465
Indirizzo
1000 MYLAN BOULEVARD, CANONSBURG
Compare VTRS vs TAK, HLN, TEVA, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
17.24 | 20.08B | 14.57B | -296.50M | 1.64B | -0.259 |
TAK
Takeda Pharmaceutical Co Adr
|
17.24 | 55.06B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.78 | 43.07B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.81 | 35.88B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
75.35 | 31.59B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
528.47 | 26.32B | 3.17B | 1.29B | 1.01B | 27.09 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-09 | Aggiornamento | UBS | Neutral → Buy |
| 2026-01-16 | Aggiornamento | Argus | Hold → Buy |
| 2025-12-09 | Iniziato | Barclays | Overweight |
| 2025-10-15 | Iniziato | Truist | Buy |
| 2025-06-06 | Iniziato | Goldman | Neutral |
| 2024-07-19 | Ripresa | Jefferies | Buy |
| 2023-10-23 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-06-23 | Downgrade | Barclays | Equal Weight → Underweight |
| 2023-04-24 | Downgrade | Barclays | Overweight → Equal Weight |
| 2023-02-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-27 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-11-10 | Aggiornamento | UBS | Sell → Neutral |
| 2022-11-08 | Aggiornamento | Piper Sandler | Underweight → Neutral |
| 2022-10-21 | Ripresa | Jefferies | Hold |
| 2022-06-14 | Iniziato | UBS | Sell |
| 2022-05-10 | Downgrade | Piper Sandler | Neutral → Underweight |
| 2022-03-01 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-03-01 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2021-06-15 | Iniziato | Citigroup | Neutral |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2021-03-08 | Downgrade | Goldman | Buy → Neutral |
| 2021-03-02 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-02-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2021-01-05 | Iniziato | Argus | Hold |
| 2020-12-14 | Iniziato | Bernstein | Mkt Perform |
Mostra tutto
Viatris Inc Borsa (VTRS) Ultime notizie
Viatris, Inc. (VTRS) Q2 2023 Earnings ReportResults, Call & Slides - TipRanks
PFE5282054 Bond Profile — Key Metrics - TradingView
Viatris, Inc. Revenue Breakdown – LSX:A2QAME - TradingView
PFE5003244 Bond Profile — Key Metrics - TradingView
Viatris Inc. stock rises Thursday, outperforms market - MarketWatch
PFE5282056 Bond Profile — Key Metrics - TradingView
Viatris Inc (VTRS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Viatris, Inc. (VTRS) Q1 2023 Earnings ReportResults, Call & Slides - TipRanks
Viatris Inc. (VTRS) Stock Forecasts - Yahoo Finance
Viatris Inc. stock falls Wednesday, underperforms market - MarketWatch
Viatris, Inc. (VIA) Q1 2023 Earnings ReportResults, Call & Slides - TipRanks
Viatris’ Quarterly Earnings Preview: What You Need to Know - Barchart.com
Viatris, Inc. (VIA) Q2 2023 Earnings ReportResults, Call & Slides - TipRanks
Viatris Inc. stock rises Tuesday, outperforms market - MarketWatch
Viatris Inc. stock falls Monday, underperforms market - MarketWatch
Viatris, Inc. (VIA) Q3 2023 Earnings ReportResults, Call & Slides - TipRanks
Viatris, Inc. (VIA) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
Viatris, Inc. (1VTRS) Q3 2023 Earnings ReportResults, Call & Slides - TipRanks
PFE5003242 Bond Profile — Key Metrics - TradingView
Viatris (VTRS) Q4 2025 Earnings Call Transcript - Fortune
Khaitan & Co Advised Viatris Inc. On Secondary Sale Of Shares Held in Biocon - BW Legal World
Is Viatris (VTRS) Reframing Its Musculoskeletal Strategy Through the AAOS Pain Management Partnership? - Sahm
Viatris stock hits 52-week high at $17.54 By Investing.com - Investing.com South Africa
Viatris stock hits 52-week high at $17.54 - Investing.com UK
Khaitan & Co, JSA, TT&A, Baker & McKenzie act on Viatris Inc's ₹3,680 crore exit from Biocon - Bar and Bench
PFE5282058 Bond Profile — Key Metrics - TradingView
Viatris Inc (VTRS) Stock Up 3.8% but GF Value Says Overvalued -- GF Score: 58/100 - GuruFocus
Viatris (VTRS) Q1 2026 Earnings Call Transcript - Fortune
Viatris Inc. stock rises Wednesday, outperforms market - MarketWatch
Viatris Looks to New Launches and Cost Savings for Long-Term Growth - Morningstar
XS332542958 Bond Profile — Key Metrics - TradingView
ETFs Investing in Viatris, Inc. Stocks - TradingView
Mylan to sell up to $363 million stake in India’s Biocon, term sheet shows - WTVB
Viatris unit Mylan plans to sell stake worth up to $363 million in Biocon - Business Standard
Mylan to sell up to $363 million stake in India's Biocon, term sheet shows - Reuters
(VTRS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Viatris shares break six-session winning streak - MSN
BofA Securities Maintains Viatris(VTRS.US) With Sell Rating, Raises Target Price to $14 - Moomoo
Viatris Inc. stock falls Thursday, underperforms market - MarketWatch
Novartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026? - The Motley Fool
Should Value Investors Buy Viatris (VTRS) Stock? - Yahoo Finance
Positive IgA Nephropathy Data And Yen Loan Recast Could Be A Game Changer For Viatris (VTRS) - simplywall.st
Viatris to Report Second-Quarter 2026 Financial Results on August 6, 2026 - AOL.com
Should Viatris’ Japan IgA Nephropathy Win and New Loan Shape VTRS Investors’ Next Move? - Yahoo Finance
Viatris Q1 2026 slides: earnings beat drives shares higher - Investing.com
Viatris (VTRS) Secures Loan Amid Positive Phase 3 Results - Yahoo Finance
Viatris (VTRS): Most Undervalued NASDAQ Stocks to Buy Right Now - Insider Monkey
Viatris Inc. Class Action: The Gross Law Firm Reminds Viatris In - GuruFocus
VTRS Stock Price and Chart — NASDAQ:VTRS - TradingView
A Look at Viatris Inc (VTRS) After 3.1% Gain -- GF Value $11.02 vs Price $16.70 - GuruFocus
Viatris (VTRS) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
Viatris Inc Azioni (VTRS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.93%
0.20%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):